Abstract: A tumor sensor system having an implantable probe and an auxiliary device, the probe having at least one sensor configured to generate an electric signal in response to a physical stimulus, the at least one sensor having a position sensor configured to sense a signal from a position tracking system, the sensed signal indicative of a position of the probe in a space, the position sensor having at least one electromagnetic sensor configured to cooperate with an external electromagnetic field generator, and the at least one electromagnetic sensor is configured to detect a property of the electromagnetic field and send it as an electric signal to the processing circuit, at least one antenna for data communication by means of inductive communication, an energy harvesting coil, and transmitting the data via the at least one antenna to the auxiliary device.

Abstract: A surgical forceps comprises a first jaw (101) and a second jaw (102), the first jaw (101) and the second jaw (102) being configured to be rotated relative to each other around an axis of rotation (104). A position sensor (105) is capable of sensing a first orientation with respect to a first axis (106) and a second orientation with respect to a second axis (107) different from the first axis (106), wherein the first axis (106) and the second axis (107) are orthogonal to the axis of rotation (104). The surgical forceps comprises a stapler (108) for stapling a tissue grasped by the surgical forceps (100) and a cutter (103) for cutting the tissue grasped by the surgical forceps (100) along a line.

Abstract: A heat and moisture exchanger, comprises a rigid monolithic body (101). The rigid monolithic body (101) comprises a circumferential wall (102); and a structure of interconnected elements (106) surrounded by the circumferential wall (102). The structure (106) is open to fluid communication through the structure (106) between a first side (114) of the structure and a second side (115) of the structure (106) opposite the first side (114) of the structure (106). The circumferential wall (102) extends from the first side (114) to the second side (115) of the structure (106). The heat and moisture exchanger (100) is open on both of the first side (114) and the second side (115) of the structure (106), to allow fluid communication between the structure (106) and an exterior of the heat and moisture exchanger (100) on both sides (114, 115).

Abstract: In a method to determine a patient (radiation) dose distribution (13), it is provided to calculate, from a measured signal (7) of a detector (6) placed behind a region of interest, a dose distribution (11) for a patient-shaped water equivalent phantom (12) and to compute from this a patient dose distribution (13) that takes into account inhomogeneities of a matter distribution of the patient (4).

Abstract: The invention is concerned with use of oral inorganic pyrophosphate for preventing and/or reducing tissue calcification, particularly soft tissue calcification, and/or diseases or disorders characterized by low plasma PPi levels, as, e.g.

Abstract: The present invention relates to active agents or compounds as well as pharmaceutical compositions comprising said compounds, which are capable of reducing or inhibiting or blocking the enzymatic activity of the glutaminyl-peptide cyclotransferase (QPCT) protein, the glutaminyl-peptide cyclotransferase-like protein (QPCTL) protein, or combinations thereof or are capable of reducing or inhibiting the expression of QPCT gene, the QPCTL gene, or combinations thereof. Also provided are methods for screening or selecting for said compounds. The present invention further relates to a pharmaceutical composition comprising a first active agent for use in a method of treating a condition in a subject that would benefit from reducing the signaling or the binding between SIRP? and CD47 in the subject (e.g. cancer), wherein the method of treating comprises reducing expression or enzymatic activity of QPCTL, QPCT, or combinations thereof in the cell with CD47 on the surface.

Abstract: Method of activating dysfunctional T cells, determining responsiveness of a subject having a tumor to an immune checkpoint inhibition are provided. Also provided is an agent capable of inhibiting a target gene or expression product thereof for use in treating a subject having a tumor. Additionally or alternatively provided is an immune checkpoint inhibitor and an agent capable of inhibiting a target gene or expression product thereof for use in treating a subject having a tumor.

Abstract: The present invention relates to TWEAK-receptor agonists for use in the treatment of a cancer, wherein the TWEAK-receptor agonist is combined with immunotherapy of the cancer. The TWEAK-receptor agonist preferably is a multivalent ligand that causes clustering of TWEAK-receptors at the cell surface. A suitable TWEAK-receptor agonist is an agonistic anti-Fn14 antibody. The TWEAK-receptor agonist and immunotherapy be can further be combined with a SMAC mimetic in the treatment of cancer. The TWEAK-receptor agonist is useful, optionally in combination with a SMAC mimetic, to prevent resistance of a cancer to immunotherapy and/or to treat a cancer comprising tumor cells that are resistant to immunotherapy.

Abstract: A surgical instrument is disclosed to remove tissue, in particular unhealthy tissue or tissue containing cancer cells, from a body and to analyse the removed tissue. A tissue removal device is arranged at a distal end of the surgical instrument, wherein the distal part of the surgical instrument comprises a movable part, for example a bendable part, to adjust a position and/or orientation of the tissue removal device with respect to a proximal end of the surgical instrument, wherein movement of the movable part can be controlled by an operator. A discharge channel is connected to the tissue removal device for discharge of removed tissue. A tissue analysis device comprises an analysis sensor to analyse non-removed tissue in front of the tissue removal device, wherein the tissue analysis device is configured to provide a sensor signal representative for an analysed characteristic of the tissue.

Abstract: The current invention relates to treatment of drug resistant melanoma with histone deacetylase inhibitors (HDACi). In particular the invention relates to BRAF and NRAS mutated melanoma and that have acquired resistance to MAPK pathway inhibitors, for example due to previous treatment with such MAPK pathway inhibitors. The invention discloses HDACi and/or MAPK pathway inhibitors for use in such treatment and treatment regimens using such inhibitors.

Abstract: In a method and apparatus, a property of an optically diffuse medium including a first optical absorber having a first concentration and a second optical absorber having a second concentration is determined. A surface area of the medium is imaged at multiple wavelengths around an isosbestic wavelength of the first absorber and the second absorber. A reflectance spectrum of the medium at the surface area at the multiple wavelengths is determined. A derivative of the determined reflectance spectrum around the isosbestic wavelength is determined. From the derivative, a concentration ratio of the first concentration and the second concentration is estimated.

Abstract: The invention provides improved screening methods for testing T cell recognition of T cell epitopes.

Abstract: The current disclosure relates to pharmaceutical combinations and compositions useful in the treatment of certain types of cancer. The disclosure also relates to method of treatment these certain types of cancer. In particular, the disclosure relates to the combined use of inhibitors of MEK, EGFR and ERBB2 in the treatment of KRAS-mutant lung cancer, and KRAS-mutant colon cancer.

Abstract: The present invention comprises generally applicable methods for identifying endogenous physiologically relevant genetic elements that affects a intracellular phenotype of interest. In the methods, non-living cells that have been subjected to a mutagenesis treatment are sorted based on phenotype and analyzed to identify the genetic element. By use of these methods, elements previously unknown to be involved in a phenotype can be identified, for example in relationship to health conditions, external stress or drug response, in particular in cancer.

Abstract: In a method and system for providing visual information about a tumour location in human or animal body, an electromagnetic tumour sensor is provided in the tumour and tracked to determine its location in space, which is mapped to a tumour model. A surgical tool sensor is provided on a surgical tool, and tracked to determine its location in space, which is mapped to a surgical tool model. The body is scanned to obtain information about an anatomical structure. A reference sensor is provided on the body, and tracked to determine its location in space, which is mapped to the anatomical structure. A virtual image is displayed showing the tumour model, located with the at least one tumour sensor, in spatial relationship to the surgical tool model, located with the at least one surgical tool sensor, and the anatomical structure, located with the at least one reference sensor.

Abstract: The present invention concerns compounds that are capable of covalently entrapping adenylating enzymes. The present invention is essentially based on the discovery that analogues of adenylating enzyme (AE) substrates, wherein a methylene group has been incorporated at the carbon atom in the ?-position relative to the carboxylate group involved in the adenylation, are capable of undergoing the adenylation reaction, thereby creating an activated methylene group in situ. The resulting ‘armed’ acyladenylate can interact with the enzyme resulting in covalent entrapment. Interestingly, the acyladenylate can alternatively be transferred to the next step in the enzyme cascade, following which the activated methylene group can interact with the next (active site cysteine containing) enzyme in the enzymatic cascade.

Abstract: The instant application provides methods and related compositions pertaining to the identification of resistance to anticancer treatment in. a patient. In a particular embodiment, the invention provides biomarkers for the identification of resistance to anticancer treatment in a breast cancer patient, wherein a reduced expression of a MEDIATOR and/or SWI/SNF complex gene in the breast cancer cells of the patient indicates that the breast cancer cells in the patient may be successfully treated with a PI3K and/or mTOR inhibitor.